Related Experiment Video
Updated: May 22, 2026
09:32
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Methodological and preanalytical evaluation of a RAGE immunoassay
Christin Wittwer1, Julia Lehner, Debora Fersching
1Institute of Clinical Chemistry, University Hospital Munich-Grosshadern, Munich, Germany.
Anticancer Research
|May 18, 2012
Summary
Soluble receptor of advanced glycation end products (sRAGE) ELISA is a robust assay for monitoring diseases. This method provides reliable quantitative results for serum and plasma, proving safe for clinical use.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Biomarker Discovery
Background:
- Soluble receptor of advanced glycation end products (sRAGE) is a key biomarker.
- sRAGE shows promise in monitoring cancer, trauma, and sepsis prognosis.
Purpose of the Study:
- To investigate the methodological characteristics of an sRAGE ELISA kit (R&D Diagnostics).
- To assess the impact of preanalytical factors on sRAGE measurements.
- To establish a reference range for sRAGE in healthy individuals.
Main Methods:
- ELISA imprecision, dilution linearity, and recovery in various serum and plasma matrices were evaluated.
- Preanalytical factors including storage time, temperature, centrifugation, and freeze-thaw cycles were tested.
- Sera from 30 healthy individuals were used to establish a reference range.
Main Results:
- Intra-assay (6.0-11.5% CV) and inter-assay (5.9-7.8% CV) imprecision were acceptable.
- Dilution linearity showed 99-131% recovery; serum, EDTA-plasma, and heparin-plasma yielded comparable results.
- No significant influence of preanalytical factors (time, temperature, freeze-thaw) on sRAGE levels was observed.
Conclusions:
- The sRAGE ELISA is a robust and safe assay.
- Reliable quantitative results can be obtained from both serum and plasma samples.
- The assay is suitable for clinical monitoring and prognostic applications.
